Art

J-GLOBAL ID：201902276591573993   Reference number：19A1165770

Once-weekly teriparatide reduces serum sclerostin levels in postmenopausal women with osteoprosis

テリパラチド週1回投与は骨粗鬆症の閉経後女性における血清スクレロスチンレベルを低下させる

Author (4)： Ikeda Terumasa (Division of Orthopedic Surgery, Kindai University Faculty of Medicine, Ohnohigashi, Osakasayama 589-8511, Japan) ,  Kaji Hiroshi (Department of Physiology and Regenerative Medicine, Kindai University Faculty of Medicine) ,  Tamura Yukinori (Department of Physiology and Regenerative Medicine, Kindai University Faculty of Medicine) ,  Akagi Masao (Division of Orthopedic Surgery, Kindai University Faculty of Medicine, Ohnohigashi, Osakasayama 589-8511, Japan)
Material： Journal of Orthopaedic Science  (J Orthop Sci)
Volume： 24  Issue： 3  Page： 532-538  Publication year： May. 2019 
JST Material Number： L3245A  ISSN： 0949-2658  CODEN： JOSCFS  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： Teriparatide ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1165770&from=J-GLOBAL&jstjournalNo=L3245A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D) ,  Clinical application of other drugs  (GW23020V)

Reference (28)：

• Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012 Oct 33;(5):747-83.
• Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 May 10;344(19):1434-41.
• Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Soen S, Yoshikawa H, Nishizawa Y, Fujita t, Shiraki M. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012 Sep;97(9):3097-106.
• Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Soen T, Kuroda T, Nakamura T. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metabol 2014 Jul;32(4):441-6.
• Takeuchi Y, Kuroda T, Sugimoto T, Shiraki M, Nakamura T. Renal phosphate reabsorption is correlated with the increase in lumbar bone mineral density in patients receiving once-weekly teriparatide. Calcif Tissue Int 2016 Feb;98(2):186-92.

Terms in the title (6)： テリパラチド ,  週1回投与 ,  骨粗鬆症 ,  閉経後女性 ,  血清 ,  スクレロスチン